Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COVERA-HS vs AMVAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Verapamil hydrochloride is a phenylalkylamine calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, thereby reducing afterload and myocardial contractility. In the heart, it slows atrioventricular conduction and prolongs the effective refractory period; in vascular smooth muscle, it causes vasodilation, reducing peripheral vascular resistance.
AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.
Hypertension,Angina pectoris including chronic stable angina, vasospastic (Prinzmetal's) angina, and unstable angina,Supraventricular tachyarrhythmias including atrial fibrillation/flutter and paroxysmal supraventricular tachycardia
FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
180 mg orally once daily at bedtime, extended-release tablet. Maximum dose 540 mg/day.
Intravenous: 500 mg every 6 hours.
Terminal elimination half-life is 6–17 hours for immediate-release; for Covera-HS (controlled-onset extended-release), the half-life is 10–20 hours, allowing once-daily bedtime dosing to achieve peak effect in the morning.
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Primarily hepatic metabolism via cytochrome P450 enzymes, including CYP3A4, CYP2C8, and CYP1A2, with extensive first-pass effect. Major metabolites include norverapamil (active) and various dealkylated and conjugated metabolites.
AMVAZ is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Primarily hepatic metabolism (oxidation and glucuronidation) with renal excretion of inactive metabolites; approximately 80% of metabolites are excreted renally and 15% fecally.
Primarily renal excretion of unchanged drug (60-70%) and metabolites (10-20%); biliary/fecal excretion accounts for 15-25%.
95–98% bound to plasma proteins, primarily to albumin.
98% bound to albumin primarily, with minor binding to alpha-1-acid glycoprotein.
2.0–2.5 L/kg, indicating extensive tissue distribution.
0.2-0.3 L/kg, indicating minimal extravascular distribution and confinement to plasma volume.
Oral: 70–86% due to first-pass metabolism.
Oral bioavailability is 85-95%; reduced to 60-70% when taken with high-fat meals.
GFR 30-80 m L/min: no adjustment; GFR <30 m L/min: start at 180 mg daily, titrate cautiously. Not dialyzable.
Cr Cl 30-50 m L/min: 250 mg every 6 hours; Cr Cl 15-29 m L/min: 250 mg every 12 hours; Cr Cl <15 m L/min: 250 mg every 24 hours; hemodialysis: 250 mg after dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Safety and efficacy not established; no recommended dosing.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Start at 180 mg orally once daily; titrate slowly due to increased sensitivity and reduced clearance.
Consider renal function; start at lower end of dosing range due to age-related decreased renal clearance.
None
None
May cause hypotension, especially in patients with ventricular dysfunction,Can precipitate heart failure or worsen pre-existing heart failure,Risk of bradycardia and heart block, especially in patients with sick sinus syndrome or pre-existing conduction defects,Caution in patients with hypertrophic cardiomyopathy due to risk of worsening obstruction and hypotension,Avoid abrupt withdrawal in patients with angina; may cause severe exacerbation,May increase serum levels of digoxin, cyclosporine, and other CYP3A4 substrates,Use with caution in patients with hepatic impairment due to reduced clearance,May cause symptomatic hypotension when administered with beta-blockers or other antihypertensives,Monitor for constipation, especially in elderly patients
Infusion-related reactions (IRRs): premedicate and monitor during infusion; interrupt or discontinue if severe.,Interstitial lung disease (ILD)/pneumonitis: monitor for new or worsening respiratory symptoms; withhold or permanently discontinue.,Dermatologic adverse reactions (rash, dry skin, pruritus): manage with topical corticosteroids, emollients, and oral antihistamines; consider dose modification.,Ocular toxicity: monitor for keratitis, uveitis; refer to ophthalmology if symptoms develop.,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception.
Severe left ventricular dysfunction (ejection fraction <30%),Hypotension (systolic blood pressure <90 mm Hg),Cardiogenic shock,Sick sinus syndrome (unless pacemaker in place),Second- or third-degree AV block (unless pacemaker in place),Atrial fibrillation/flutter with accessory bypass tract (e.g., Wolff-Parkinson-White syndrome),Known hypersensitivity to verapamil or any component of the formulation,Concurrent use of ivabradine
None
Avoid grapefruit and grapefruit juice; may increase verapamil serum concentrations. Limit alcohol intake; can potentiate hypotensive effects and increase risk of bradycardia. High-fat meals may delay absorption but do not significantly alter AUC; take consistently with food.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing amiodarone levels and risk of toxicity. Limit alcohol consumption due to potential hepatotoxicity. High-fat meals may increase absorption; take consistently with or without food.
First trimester: No increased risk of major congenital malformations based on limited human data; animal studies show fetotoxicity at high doses. Second/third trimester: Associated with fetal hypotension, oligohydramnios, intrauterine growth restriction (IUGR), and hypocalcemia. May cause preterm delivery and neonatal renal impairment.
No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters: no known fetal harm.
Verapamil (active ingredient) is excreted into human breast milk at low concentrations (M/P ratio ~0.6-0.8). Estimated infant dose is <0.1% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for hypotonia, bradycardia, and constipation.
No data on excretion in human milk; M/P ratio unknown. Caution recommended; benefits of breastfeeding should be weighed against potential risk to infant.
No specific dose adjustments are routinely recommended; however, pharmacokinetic changes in pregnancy (increased plasma volume, increased renal clearance) may necessitate dose titration based on clinical response. Consider using lowest effective dose to minimize fetal hypotension and hypoperfusion.
No specific dose adjustments required in pregnancy; pharmacokinetic changes not well-characterized. Use lowest effective dose and monitor clinical response.
Covera-HS (verapamil extended-release) is formulated for bedtime dosing to maximize blood pressure control during early morning surge. Avoid use in patients with pre-excited atrial fibrillation (Wolff-Parkinson-White syndrome) due to risk of ventricular fibrillation. Monitor for constipation, especially in elderly. Adjust dose in hepatic impairment; contraindicated in severe left ventricular dysfunction and hypotension.
AMVAZ (amiodarone) has a long half-life (up to 107 days) and can cause thyroid, pulmonary, hepatic, and skin toxicity. Monitor thyroid function (TSH, T3, T4), liver enzymes (ALT, AST), and perform baseline pulmonary function tests and chest X-ray. Corneal microdeposits are common and may cause visual halos; usually reversible. Administer loading dose to achieve therapeutic effect more quickly. Avoid use with grapefruit juice as it increases drug levels.
Take exactly as prescribed, usually once daily at bedtime, with food to minimize gastrointestinal irritation.,Swallow tablet whole; do not crush, chew, or break.,Do not discontinue abruptly; may cause rebound hypertension or angina.,Avoid grapefruit juice and alcohol; they can increase verapamil levels or enhance side effects.,Report symptoms such as slow heartbeat, dizziness, fainting, or swelling of ankles/feet.
Take AMVAZ exactly as prescribed; do not stop without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking this medication.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations immediately.,Notify your doctor if you experience vision changes, yellowing of skin/eyes, dark urine, or unusual fatigue.,Use effective contraception during treatment and for at least 6 months after stopping.,Avoid excessive sun exposure; use sunscreen and protective clothing due to risk of skin discoloration and photosensitivity.,Do not take over-the-counter medications or herbal supplements without checking with your doctor.,Regular blood tests and eye exams are necessary while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COVERA-HS vs AMVAZ, answered by our medical review team.
COVERA-HS is a Calcium Channel Blocker that works by Verapamil hydrochloride is a phenylalkylamine calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, thereby reducing afterload and myocardial contractility. In the heart, it slows atrioventricular conduction and prolongs the effective refractory period; in vascular smooth muscle, it causes vasodilation, reducing peripheral vascular resistance.. AMVAZ is a Calcium Channel Blocker that works by AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COVERA-HS and AMVAZ depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COVERA-HS is: 180 mg orally once daily at bedtime, extended-release tablet. Maximum dose 540 mg/day.. The standard adult dose of AMVAZ is: Intravenous: 500 mg every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COVERA-HS and AMVAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COVERA-HS is classified as Category C. First trimester: No increased risk of major congenital malformations based on limited human data; animal studies show fetotoxicity at high doses. Second/third trimester: Associated. AMVAZ is classified as Category C. No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.